Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
- Author
- ReachMD
- Published
- Fri 20 Jun 2025
- Episode Link
- http://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/
CME credits: 1.00
Valid until: 20-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/
Valid until: 20-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/
Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date!
=